ArticleCureus2026
Dravet Syndrome Associated With a CSNK2B-Related Neurodevelopmental Disorder.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dravet syndrome (DS) is a developmental epileptic encephalopathy characterized by prolonged febrile and afebrile focal clonic as well as generalized seizures. The most common genetic etiology is SCN1A, but other genetic disorders can present with the phenotype. A two-year-and-11-month-old Caucasian female patient of Russian descent, with a history of developmental delay and recurrent prolonged febrile focal clonic seizures since the age of 2-3 months, presented with afebrile status epilepticus. Genetic testing identified a de novo mutation in CSNK2B. Her clinical history and semiology were consistent with DS. The CSNK2B mutation is associated with neurodevelopmental disorders characterized by developmental delays and epilepsy of varying severity. This is the first reported case of a child with a CSNK2B mutation presenting with a DS phenotype. The pathophysiological mechanisms of CSNK2B mutations involve disrupted casein kinase 2 (CK2) activity, which impacts synaptic plasticity and shares similarities with the synaptic dysfunction seen in other genes associated with the DS phenotype. Identifying such cases expands the knowledge base and understanding of the genetic landscape of DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.